Haleon plc has disclosed its total voting rights and capital in a recent filing, which is significant for shareholders and stakeholders in the consumer health sector. As of October 31, 2026, the company has issued a total of 8,808,341,409 ordinary shares, of which 16,238,543 are held as treasury shares. This leaves 8,792,102,866 ordinary shares with voting rights.

This update is crucial as it provides shareholders with the necessary information to determine if they need to notify any changes in their interests in the company, as per the Financial Conduct Authority's Disclosure Guidance and Transparency Rules.

Background

Haleon plc, listed on the NYSE under the ticker HLN and on the OTC as HLNCF, operates within the perfumes, cosmetics, and other toilet preparations industry (SIC: 2844). The company focuses on everyday health and offers a range of products across various categories, including oral health, vitamins, pain relief, and more. Haleon’s brands are trusted by consumers globally, making it a significant player in the consumer health market.

What the Filing Says

The filing states, "As at 31 October 2026 the total number of shares issued by Haleon plc is 8,808,341,409 ordinary shares of £0.01 each, of which 16,238,543 are held as treasury shares." It further clarifies that the number of ordinary shares with voting rights is 8,792,102,866, which shareholders should use for any notifications regarding their interests.

Impact

This information impacts shareholders and potential investors who must comply with regulations regarding their interests in the company. It also serves as a reminder for stakeholders to stay informed about Haleon’s governance and shareholder structure.

What's Next

The filing does not say what happens next.